Sanofi (NASDAQ:SNY) Given Consensus Recommendation of “Hold” by Brokerages

Sanofi (NASDAQ:SNY) has received an average rating of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $55.00.

Several brokerages recently weighed in on SNY. TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley started coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target for the company. Finally, JPMorgan Chase & Co. downgraded shares of Sanofi from an “overweight” rating to a “neutral” rating in a report on Tuesday, December 5th.

Sanofi Price Performance

NASDAQ:SNY opened at $48.60 on Friday. The firm’s fifty day moving average is $48.12 and its two-hundred day moving average is $49.41. The firm has a market cap of $122.94 billion, a price-to-earnings ratio of 20.59, a PEG ratio of 1.84 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a one year low of $42.63 and a one year high of $57.82.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. Research analysts expect that Sanofi will post 4.19 EPS for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be paid a $1.478 dividend. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio is currently 58.05%.

Institutional Investors Weigh In On Sanofi

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. SRS Capital Advisors Inc. boosted its position in Sanofi by 289.1% during the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock worth $25,000 after acquiring an additional 344 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC purchased a new position in Sanofi in the 3rd quarter worth approximately $26,000. Indiana Trust & Investment Management CO acquired a new position in shares of Sanofi during the 3rd quarter worth approximately $27,000. Fairfield Bush & CO. acquired a new stake in shares of Sanofi in the first quarter valued at approximately $26,000. Finally, Rise Advisors LLC lifted its position in Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after buying an additional 251 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.